Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Yuting Yan, Xiaoqi Qin, Lanting Liu, Shuhui Deng, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Fu Mingwei, MD, Xue-Han Mao, MD, Zhen Yu, MD, Dehui Zou, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143447

Published: 2020

Journal Articles

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Chenxing Du, MD, Xue-Han Mao, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, MD, Wenyang Huang, Yan Xu, Chengwen Li, Jiawei Zhao, Dehui Zou, MD, Yaozhong Zhao, Jianxiang Wang, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140909

Published: 2020

Journal Articles

Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Blood (2020) 136 (Supplement 1): 38–41.

https://doi.org/10.1182/blood-2020-136108

Published: 2020

Journal Articles

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial

Gang An, MD PhD, Daobin Zhou, MD PhD, Weili Zhao, MD PhD, Keshu Zhou, MD PhD, Jianyong Li, MD PhD, Jianfeng Zhou, MD PhD, Liping Xie, MD PhD, Jie Jin, MD PhD, Liye Zhong, MD PhD, Lingzhi Yan, MD PhD, Haiyi Guo, MD, Chenmu Du, MD, Jane Huang, MD, William Novotny, MD, Jinhua Zhong, PhD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136783

Published: 2020

Journal Articles

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Ryu Lv, Yi Wang, Tingyu Wang, Xiong Wenjie, Huijun Wang, Yuting Yan, Qi Wang, Wei Liu, Gang An, MD PhD, Wenyang Huang, Weiwei Sui, MD, Yan Xu, MD, Zhen Yu, MD, Dehui Zou, MD, Jianxiang Wang, MD, Lugui Qiu, MD, Shuhua Yi, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-138592

Published: 2020

Journal Articles

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-138734

Published: 2020

Journal Articles

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

Yi Wang, Jing Zhuang, Gang An, MD PhD, Xue-Han Mao, MD, Chenxing Du, MD, Jiahui Liu, Huishou Fan, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-141188

Published: 2020

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Chenxing Du, MD, Yi Wang, Xue-Han Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Yan Xu, Weiwei Sui, MD, Shuhui Deng, MD, Fu Mingwei, MD, Chengwen Li, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Yaozhong Zhao, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140718

Published: 2020

Journal Articles

Plasma Cell Leukemia in China: Retrospective Analysis of Clinical Characteristics and Prognosis

Tengteng Yu, MD, Yan Xu, MD, PhD, Gang An, MD PhD, Zengjun Li, MD, PhD, Mu Hao, MD, PhD, Lugui Qiu, MD

Blood (2016) 128 (22): 5619.

https://doi.org/10.1182/blood.V128.22.5619.5619

Published: 2016

Journal Articles

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Reverse Immunosuppression in Multiple Myeloma

Xiaoyan Feng, Chirag Acharya, MD, Gang An, MD PhD, Kenneth Wen, Li Zhang, Alireza Kalbasi, Lugui Qiu, MD, Nikhil C Munshi, MD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 2106.

https://doi.org/10.1182/blood.V128.22.2106.2106

Published: 2016

Journal Articles

Osteoclasts Promote Immune Suppressive Microenvironment in Multiple Myeloma: Therapeutic Implication

Gang An, MD PhD, Chirag Acharya, Xiaoyan Feng, MD, Kenneth Wen, Mike Zhong, BS, Li Zhang, Nikhil C Munshi, MD, Lugui Qiu, MD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 3303.

https://doi.org/10.1182/blood.V128.22.3303.3303

Published: 2016

Journal Articles

Unmeasurable Serum M-Protein Multiple Myeloma Benefit Less from Bortezomib Than Measurable Myeloma

Xiaoqi Qin, Gang An, MD PhD, Yan Xu, MD PhD, Yu Qin, PhD, Xiaoyan Feng, MD, Meirong Zang, PhD, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, Wen Zhou, PhD, Lugui Qiu, MD

Blood (2014) 124 (21): 2062.

https://doi.org/10.1182/blood.V124.21.2062.2062

Published: 2014

Journal Articles

A Novel Anti-a Proliferation-Inducing Ligand Hapril.01A Monoclonal Antibody Targets Multiple Myeloma Cells in the Bone Marrow Microenvironment

Yu-Tzu Tai, PhD, Chirag Acharya, MD, Gang An, MD PhD, Mike Y Zhong, Michele Cea, MD, Antonia Cagnetta, MD, Hua Jiang, MDPhD, Hans van Eenennaam, PhD, Andrea van Elsas, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson

Blood (2014) 124 (21): 2098.

https://doi.org/10.1182/blood.V124.21.2098.2098

Published: 2014

Journal Articles

SAR 650984, a Therapeutic Anti-CD38 Monoclonal Antibody, Blocks CD38-CD31 Interaction in Multiple Myeloma

Gang An, MD PhD, Hua Jiang, MDPhD, Chirag Acharya, MD, Mike Y Zhong, BS, Ti Cai, PhD, Guang Yang, Zhili Song, Joachim Theilhaber, PhD, Francisco Adrian, PhD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD

Blood (2014) 124 (21): 4729.

https://doi.org/10.1182/blood.V124.21.4729.4729

Published: 2014

Journal Articles

MiR-137 Contributes to Drug Susceptibility and Chromosomal Instability of Multiple Myeloma through Targeting AURKA

Yu Qin, PhD, Fei Li, MD, Xiaoqi Qin, Gang An, MD PhD, Mu Hao, PhD, Meirong Zang, PhD, Yan Xu, MD PhD, Wen Zhou, PhD, Hong Chang, Lugui Qiu, MD

Blood (2014) 124 (21): 5715.

https://doi.org/10.1182/blood.V124.21.5715.5715

Published: 2014

Journal Articles

Hypermethylation of TAp73 Suppresses ABL1-Involved DNA Damage Response in Multiple Myeloma

Mu Hao, PhD, Yu Qin, PhD, Meirong Zang, PhD, Yan Xu, MD PhD, Gang An, MD PhD, Changhong Li, MD, Ye Yang, PhD, Zhimin Gu, PhD, Fenghuang Zhan, MD PhD, Lugui Qiu, MD PhD

Blood (2014) 124 (21): 3374.

https://doi.org/10.1182/blood.V124.21.3374.3374

Published: 2014

Journal Articles

NFκB Signaling and Mcl-1 Are Critical in B Cell Maturation Antigen-Promoted Multiple Myeloma Cell Growth and Survival

Chirag Acharya, MD, Gang An, MD PhD, Mike Y Zhong, Michele Cea, MD, Antonia Cagnetta, MD, Hua Jiang, MDPhD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD

Blood (2014) 124 (21): 3384.

https://doi.org/10.1182/blood.V124.21.3384.3384

Published: 2014

Journal Articles

Clonal Heterogeneityand Evolutional Paths in Multiple Myeloma Revealed By QM-FISH in Single Cell of Sequential Analysis

Xiaoqi Qin, Gang An, MD PhD, Yu Qin, PhD, Yan Xu, MD PhD, Xiaoyan Feng, MD, Meirong Zang, PhD, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, Wen Zhou, PhD, Lugui Qiu, MD PhD

Blood (2014) 124 (21): 3395.

https://doi.org/10.1182/blood.V124.21.3395.3395

Published: 2014

Journal Articles

SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide

Hua Jiang, MDPhD, Gang An, MD PhD, Chirag Acharya, MD, Mike Y Zhong, BS, Ti Cai, PhD, Zhili Song, Guang Yang, Francisco Adrian, PhD, Nikhil C. Munshi, MD, Yu-Tzu Tai, PhD, Kenneth C. Anderson

Blood (2014) 124 (21): 2124.

https://doi.org/10.1182/blood.V124.21.2124.2124

Published: 2014

NARROW

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Plasma Cell Leukemia in China: Retrospective Analysis of Clinical Characteristics and Prognosis

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Reverse Immunosuppression in Multiple Myeloma

Osteoclasts Promote Immune Suppressive Microenvironment in Multiple Myeloma: Therapeutic Implication

Unmeasurable Serum M-Protein Multiple Myeloma Benefit Less from Bortezomib Than Measurable Myeloma

A Novel Anti-a Proliferation-Inducing Ligand Hapril.01A Monoclonal Antibody Targets Multiple Myeloma Cells in the Bone Marrow Microenvironment

SAR 650984, a Therapeutic Anti-CD38 Monoclonal Antibody, Blocks CD38-CD31 Interaction in Multiple Myeloma

MiR-137 Contributes to Drug Susceptibility and Chromosomal Instability of Multiple Myeloma through Targeting AURKA

Hypermethylation of TAp73 Suppresses ABL1-Involved DNA Damage Response in Multiple Myeloma

NFκB Signaling and Mcl-1 Are Critical in B Cell Maturation Antigen-Promoted Multiple Myeloma Cell Growth and Survival

Clonal Heterogeneityand Evolutional Paths in Multiple Myeloma Revealed By QM-FISH in Single Cell of Sequential Analysis

SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only